

## Financial Tear Sheet

### Corporate Profile

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

### Stock Information

XBIT (Common Stock)	
<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	\$4.47
<b>Change (%)</b>	0.00 (0.00%)
<b>Volume</b>	472
<b>52 Week Low</b>	\$2.77
<b>Market Cap</b>	\$158,406,841
<b>Rolling EPS</b>	-1.26
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	35,437,772
Data as of 12/14/17 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

### Recent News

Date	Title
12/04/17	XBiotech Announces Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study in The Journal of Investigative Dermatology
11/14/17	XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions
11/03/17	XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions

### Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
11/22/17	4
11/22/17	8-K
11/09/17	10-Q
09/15/17	8-K

## Management

John Simard	Founder, President, Chief Executive Officer & Chairman
Norma I. Gonzalez	Vice President of Quality
Benjamin Guzman	Senior Vice President of Corporate Strategy & Finance
Queena Han, C.P.A., C.G.A.	Vice President of Finance and Human Resources and Secretary
Sushma Shivaswamy, Ph.D.	Chief Scientific Officer
Michael Stecher, M.D.	Medical Director

## Primary IR Contact

James S. Whitehurst  
XBiotech  
**Phone:** +1 512.386.2993  
**Email:** swhitehurst@xbiotech.com

## Board of Directors

John Simard	Founder, President, Chief Executive Officer & Chairman
Thorpe McKenzie	Director
Daniel Vasella, M.D.	Director